PL2214646T3 - Dendrymery do przedłużonego uwalniania związków - Google Patents

Dendrymery do przedłużonego uwalniania związków

Info

Publication number
PL2214646T3
PL2214646T3 PL08835693T PL08835693T PL2214646T3 PL 2214646 T3 PL2214646 T3 PL 2214646T3 PL 08835693 T PL08835693 T PL 08835693T PL 08835693 T PL08835693 T PL 08835693T PL 2214646 T3 PL2214646 T3 PL 2214646T3
Authority
PL
Poland
Prior art keywords
dendrimers
compounds
sustained release
sustained
release
Prior art date
Application number
PL08835693T
Other languages
English (en)
Inventor
Kannan Rangaramanujam
Raymond Iezzi
Bharath Raja Guru
Sujatha Kannan
Original Assignee
Wayne State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University filed Critical Wayne State University
Publication of PL2214646T3 publication Critical patent/PL2214646T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/028—Polyamidoamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L101/00—Compositions of unspecified macromolecular compounds
    • C08L101/005—Dendritic macromolecules
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
    • C08L79/02—Polyamines
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
PL08835693T 2007-10-05 2008-10-06 Dendrymery do przedłużonego uwalniania związków PL2214646T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99798707P 2007-10-05 2007-10-05
US13580908P 2008-07-23 2008-07-23
PCT/US2008/078988 WO2009046446A2 (en) 2007-10-05 2008-10-06 Dendrimers for sustained release of compounds
EP08835693.6A EP2214646B1 (en) 2007-10-05 2008-10-06 Dendrimers for sustained release of compounds

Publications (1)

Publication Number Publication Date
PL2214646T3 true PL2214646T3 (pl) 2021-12-20

Family

ID=40526988

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08835693T PL2214646T3 (pl) 2007-10-05 2008-10-06 Dendrymery do przedłużonego uwalniania związków

Country Status (9)

Country Link
US (4) US10463609B2 (pl)
EP (1) EP2214646B1 (pl)
JP (1) JP5484339B2 (pl)
CA (1) CA2701291A1 (pl)
DK (1) DK2214646T3 (pl)
HU (1) HUE055815T2 (pl)
PL (1) PL2214646T3 (pl)
PT (1) PT2214646T (pl)
WO (1) WO2009046446A2 (pl)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
KR101406415B1 (ko) 2005-07-15 2014-06-19 미셀 테크놀로지즈, 인코포레이티드 제어된 형태의 약물 분말을 함유하는 중합체 코팅
PL2019657T3 (pl) 2006-04-26 2015-10-30 Micell Technologies Inc Powłoki zawierające wiele leków
US9539593B2 (en) * 2006-10-23 2017-01-10 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
JP5603598B2 (ja) 2007-01-08 2014-10-08 ミセル テクノロジーズ、インコーポレイテッド 生物分解層を有するステント
EP2146758A4 (en) * 2007-04-17 2012-11-21 Micell Technologies Inc STENTS WITH BIODEGRADABLE LAYERS
WO2008148013A1 (en) * 2007-05-25 2008-12-04 Micell Technologies, Inc. Polymer films for medical device coating
JP5484339B2 (ja) 2007-10-05 2014-05-07 ウェイン ステート ユニバーシティー 合成物の持続的な放出のためのデンドリマー
US20100298928A1 (en) * 2007-10-19 2010-11-25 Micell Technologies, Inc. Drug Coated Stents
AU2009251504B2 (en) 2008-04-17 2013-09-05 Micell Technologies, Inc. Stents having bioabsorbable layers
CA2730995C (en) 2008-07-17 2016-11-22 Micell Technologies, Inc. Drug delivery medical device
WO2011009096A1 (en) 2009-07-16 2011-01-20 Micell Technologies, Inc. Drug delivery medical device
US8834913B2 (en) * 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
CA2756386C (en) * 2009-03-23 2019-01-15 Micell Technologies, Inc. Drug delivery medical device
WO2010111238A2 (en) * 2009-03-23 2010-09-30 Micell Technologies, Inc. Improved biodegradable polymers
JP2012522589A (ja) * 2009-04-01 2012-09-27 ミシェル テクノロジーズ，インコーポレイテッド 被覆ステント
WO2010117460A1 (en) * 2009-04-08 2010-10-14 Michigan Molecular Institute Surface modification of reverse osmosis membranes by hydrophilic dendritic polymers
CA2759015C (en) 2009-04-17 2017-06-20 James B. Mcclain Stents having controlled elution
WO2010147831A1 (en) * 2009-06-15 2010-12-23 Wayne State University Dendrimer based nanodevices for therapeutic and imaging purposes
US20110189291A1 (en) * 2009-08-04 2011-08-04 Hu Yang Dendrimer hydrogels
WO2011053803A2 (en) * 2009-10-30 2011-05-05 The Ohio State University Multi-functional biodegradable particles for selectable targeting, imaging, and therapeutic delivery and use thereof for treating ocular disorders
WO2011097103A1 (en) * 2010-02-02 2011-08-11 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
JP2013523651A (ja) * 2010-03-24 2013-06-17 ノースイースタン ユニヴァーシティ 多重コンパートメントのマクロファージ送達
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
CA2797110C (en) 2010-04-22 2020-07-21 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
US8211450B2 (en) * 2010-05-05 2012-07-03 Senju Usa, Inc. Ophthalmic composition
CA2805631C (en) 2010-07-16 2018-07-31 Micell Technologies, Inc. Drug delivery medical device
WO2012034079A2 (en) 2010-09-09 2012-03-15 Micell Technologies, Inc. Macrolide dosage forms
US9801831B2 (en) 2010-12-30 2017-10-31 Nanyang Technological University Device for controlled release of a bioactive agent
WO2012166819A1 (en) 2011-05-31 2012-12-06 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
WO2013012689A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
EP2750662A4 (en) 2011-08-31 2015-06-24 Univ Georgia NANOPARTICLES TARGETING APOPTOSIS
EP2755692B1 (en) 2011-09-14 2020-11-25 Northwestern University Nanoconjugates able to cross the blood-brain barrier
TWI462752B (zh) 2011-09-21 2014-12-01 Univ Nat Cheng Kung 包覆疏水性藥物之膠囊粒子製造方法
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
EP2814496B1 (en) 2012-02-17 2018-04-11 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
US20150087671A1 (en) * 2012-05-16 2015-03-26 Micell Technologies, Inc. Low burst sustained release lipophilic and biologic agent compositions
US9737611B2 (en) 2012-05-21 2017-08-22 University Of Miami Dendrimer conjugates for coating cells
WO2014043576A1 (en) * 2012-09-13 2014-03-20 Starpharma Pty Limited Method of treatment or prophylaxis of infections of the eye
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
JP6330024B2 (ja) 2013-03-12 2018-05-23 マイセル・テクノロジーズ，インコーポレイテッド 生体吸収性バイオメディカルインプラント
WO2014186532A1 (en) 2013-05-15 2014-11-20 Micell Technologies, Inc. Bioabsorbable biomedical implants
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
WO2015130602A2 (en) 2014-02-28 2015-09-03 Michigan Molecular Institute Sustained release composition using biobased biodegradable hyperbranched polyesters
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
EP3137116B1 (en) 2014-04-30 2020-12-16 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
US10898593B2 (en) * 2014-05-13 2021-01-26 Yale University Compositions for nanoconfinement induced contrast enhancement and methods of making and using thereof
CN114392360A (zh) * 2014-08-13 2022-04-26 约翰霍普金斯大学 树枝状聚合物组合物和在治疗神经与cns病症中的用途
CA2957721C (en) 2014-08-13 2021-04-13 The Johns Hopkins University Selective dendrimer delivery to brain tumors
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
JP6882981B2 (ja) 2014-12-30 2021-06-02 セル キュア ニューロサイエンシズ リミテッド Ｒｐｅ細胞集団およびそれを作製する方法
WO2016123125A1 (en) 2015-01-27 2016-08-04 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
ES2584534B1 (es) * 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
EP3368028A1 (en) 2015-10-29 2018-09-05 The Johns Hopkins University Denderimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders
US20170119899A1 (en) * 2015-10-29 2017-05-04 The Johns Hopkins University Compositions and methods for treatment of peroxisomal disorders and leukodystrophies
WO2017196986A1 (en) * 2016-05-10 2017-11-16 Massachusetts Institute Of Technology Dendrimer-drug conjugates, hydrogel compositions, and methods
WO2018089373A2 (en) 2016-11-08 2018-05-17 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
US20180207293A1 (en) * 2017-01-25 2018-07-26 2C Tech Corp. Nanoparticles for sustained ophthalmic drug delivery and methods of use
IL270169B2 (en) * 2017-04-27 2024-08-01 Univ Johns Hopkins Dendrimer preparations for use in angiography
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
WO2018213125A1 (en) 2017-05-13 2018-11-22 The Johns Hopkins University Stromal derived factor 1 and it's use in the prevention and treatment of erectile dysfunction
IL270594B2 (en) 2017-05-18 2024-06-01 Regeneron Pharma Protein conjugates - a drug of cyclodextrin
WO2019094952A1 (en) 2017-11-10 2019-05-16 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
AU2019205542A1 (en) 2018-01-08 2020-07-16 Regeneron Pharmaceuticals, Inc. Steroids and antibody-conjugates thereof
AU2019265632A1 (en) 2018-05-09 2021-01-07 Yale University Particles for spatiotemporal release of agents
CN112533951A (zh) 2018-05-09 2021-03-19 里珍纳龙药品有限公司 抗msr1抗体及其使用方法
PL239642B1 (pl) * 2018-08-16 2021-12-20 Pomorski Univ Medyczny W Szczecinie Kompozycja do doszklistkowego podawania białka leczniczego
CA3163892A1 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye
WO2021113651A2 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery
CN115103688A (zh) 2019-12-04 2022-09-23 阿什瓦塔治疗股份有限公司 三触角型n-乙酰半乳糖胺修饰的羟基聚酰胺基胺树枝状大分子和其使用方法
CN111249533B (zh) * 2020-01-09 2021-01-08 中国人民解放军总医院 去铁敏缓释微泡修饰的复合孔径静电纺丝支架及其制备方法
IL297531A (en) 2020-04-24 2022-12-01 Ashvattha Therapeutics Inc Dendrimer preparations and methods for treating severe acute respiratory distress syndrome
EP4138821A1 (en) 2020-04-24 2023-03-01 The Johns Hopkins University Compositions and methods comprising dendrimers and therapeutic agents
CA3202223A1 (en) 2020-11-27 2022-06-02 General Nanotherapeutics Llc Methods and compositions for treatment of immune-mediated diseases
EP4359005A1 (en) * 2021-06-24 2024-05-01 David Feifel Psychedelic drug treatment of neuropsychiatric disorders and cerebral palsy
CN118043076A (zh) 2021-09-21 2024-05-14 约翰霍普金斯大学 用于细胞内递送的小分子生物制剂的树枝状大分子缀合物
WO2023122599A1 (en) 2021-12-20 2023-06-29 The Johns Hopkins University Glycosylated dendrimers for targeted intracellular delivery
WO2023196386A1 (en) 2022-04-05 2023-10-12 The Johns Hopkins University Dendrimer compositions for targeted delivery of therapeutics to neurons
WO2024020597A1 (en) 2022-07-22 2024-01-25 The Johns Hopkins University Dendrimer-enabled targeted intracellular crispr/cas system delivery and gene editing
WO2024044760A1 (en) 2022-08-26 2024-02-29 The Johns Hopkins University Dendrimer conjugates of antidepressant and antipsychotic agents and their methods of use
WO2024044756A1 (en) 2022-08-26 2024-02-29 The Johns Hopkins University Dendrimer compositions for targeted delivery of psychedelic therapeutics
WO2024044776A1 (en) 2022-08-26 2024-02-29 The Johns Hopkins University Cannabinoid dendrimer compositions for targeted delivery

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558120A (en) 1983-01-07 1985-12-10 The Dow Chemical Company Dense star polymer
US4507466A (en) 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US4568737A (en) 1983-01-07 1986-02-04 The Dow Chemical Company Dense star polymers and dendrimers
US4587329A (en) 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
WO1995024221A1 (en) 1986-08-18 1995-09-14 The Dow Chemical Company Bioactive and/or targeted dendrimer conjugates
US6585956B2 (en) 1997-07-07 2003-07-01 The Dow Chemical Company Dendritic-platinate drug delivery system
AU751861B2 (en) 1998-02-23 2002-08-29 Massachusetts Institute Of Technology Biodegradable shape memory polymers
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US7427394B2 (en) 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
KR100379248B1 (ko) * 2000-12-04 2003-04-08 한국과학기술연구원 덴드리머를 이용한 나노 입자가 표면에 부착된무기-고분자 복합 소재 및 그 제조 방법
US7045367B2 (en) 2001-03-23 2006-05-16 Michigan Molecular Institute Nano-scaled dendrimer-based colorimetric biosensors
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
US6617040B2 (en) 2002-01-16 2003-09-09 The United States Of America As Represented By The Secretary Of The Navy Chemoselective dendrimeric compounds for use in chemical sensors
US20030180250A1 (en) * 2002-03-22 2003-09-25 Council Of Scientific And Industrial Research Compositions and complexes containing a macromolecular compound as potential anti-inflammatory agents
AU2002249486A1 (en) 2002-03-26 2003-10-08 Council Of Scientific And Industrial Research Macromolecular compounds as potential anti-inflammatory agents
JP2006513217A (ja) * 2002-12-20 2006-04-20 コントロール・デリバリー・システムズ・インコーポレイテッド 眼内用途のためのステロイド組成物
EP1594482A1 (en) * 2003-03-26 2005-11-16 LTT Bio-Pharma Co., Ltd. Intravenous nanoparticles for targeting drug delivery and sustained drug release
KR20060015534A (ko) * 2003-04-25 2006-02-17 더 펜 스테이트 리서치 파운데이션 성장 억제, 지질 유래된 생활성 화합물의 전신 전달을 위한방법 및 시스템
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
EP2264191A1 (en) 2003-11-21 2010-12-22 ANP Technologies, Inc. Asymmetrically branched polymer conjugates and microarray assays
CN1925871A (zh) 2004-01-27 2007-03-07 南加州大学 聚合物结合的抗体癌症治疗剂
US7985424B2 (en) 2004-04-20 2011-07-26 Dendritic Nanotechnologies Inc. Dendritic polymers with enhanced amplification and interior functionality
US20090104119A1 (en) * 2004-08-25 2009-04-23 Majoros Istvan J Dendrimer Based Compositions And Methods Of Using The Same
US7732427B2 (en) 2005-03-31 2010-06-08 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
US20070041934A1 (en) 2005-08-12 2007-02-22 Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
US20090192227A1 (en) 2005-08-24 2009-07-30 Rabindra Tirouvanziam N-Acetylcysteine Compositions and Methods for Treating Acute Exacerbations of Inflammatory Lung Disease
JP5377965B2 (ja) 2005-09-09 2013-12-25 ジョージア ステート ユニバーシティ リサーチ ファウンデーション、インコーポレイテッド 標的化された造影剤および造影剤を標的化するための方法
MX2007012061A (es) * 2005-10-18 2007-12-13 Allergan Inc Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.
US7432069B2 (en) 2005-12-05 2008-10-07 Sontra Medical Corporation Biocompatible chemically crosslinked hydrogels for glucose sensing
WO2007092182A2 (en) 2006-01-26 2007-08-16 University Of Massachusetts Rna interference agents for therapeutic use
PL2322183T3 (pl) * 2006-06-01 2015-01-30 Santen Sas Wykorzystanie proleku do podawania doocznego, śródszklistkowego
WO2007145520A1 (en) 2006-06-14 2007-12-21 N.V. Nutricia Anti-inflammatory composition comprising glycine and lactoferrin and the use thereof
US20100074932A1 (en) 2006-09-22 2010-03-25 Silke Talsma Antimicrobial compositions containing gallium
JP5484339B2 (ja) 2007-10-05 2014-05-07 ウェイン ステート ユニバーシティー 合成物の持続的な放出のためのデンドリマー
WO2010147831A1 (en) 2009-06-15 2010-12-23 Wayne State University Dendrimer based nanodevices for therapeutic and imaging purposes

Also Published As

Publication number Publication date
US20160279054A1 (en) 2016-09-29
EP2214646B1 (en) 2021-06-23
DK2214646T3 (da) 2021-10-04
US20200390694A1 (en) 2020-12-17
US20110034422A1 (en) 2011-02-10
EP2214646A4 (en) 2014-08-27
US11684569B2 (en) 2023-06-27
CA2701291A1 (en) 2009-04-09
US10463609B2 (en) 2019-11-05
WO2009046446A3 (en) 2009-06-04
JP2010540664A (ja) 2010-12-24
JP5484339B2 (ja) 2014-05-07
HUE055815T2 (hu) 2021-12-28
US20170216200A1 (en) 2017-08-03
PT2214646T (pt) 2021-09-29
WO2009046446A2 (en) 2009-04-09
EP2214646A2 (en) 2010-08-11

Similar Documents

Publication Publication Date Title
HUE055815T2 (hu) Vegyületek nyújtott felszabadítására alkalmas dendrimerek
IL205130A0 (en) Solid formulations of crystalline compounds
ZA201000255B (en) Substituted bicyclolactam compounds
HK1160110A1 (en) Compounds useful for inhibiting chk1
EP2152081A4 (en) NEW CONNECTIONS
EP2146745A4 (en) NOVEL CONNECTIONS
GB0705882D0 (en) Novel compounds
ZA201100123B (en) Bromine-facilitated synthesis of fluoro-sulfur compounds
EP1976488A4 (en) ALFUZOSIN PROLONGED RELEASE PREPARATIONS
GB0724498D0 (en) Slow release compositions
GB0710680D0 (en) Novel crystalline form of olmesartan medoxmil
GB0618703D0 (en) Synthesis of leikotriene compounds
PL2144919T3 (pl) Wieloetapowa synteza ibandronianu
HU0700469D0 (en) Floatingpharmaceutical composition of sustained release containing metronidazol
GB201114396D0 (en) Location of basesation
GB0703973D0 (en) Novel compounds
ZA200906779B (en) Sustained release
GB0723191D0 (en) Sustained release
ZA201101308B (en) Improved synthesis of hexahydrodibenzopyranones
GB0806596D0 (en) Novel compounds A3
GB0700077D0 (en) Novel compounds
GB0700078D0 (en) Novel compounds
GB0700363D0 (en) Novel compounds
GB0700991D0 (en) Novel compounds
GB0700993D0 (en) Novel compounds